Cumberland Pharmaceuticals Inc.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Cumberland Pharmaceuticals Inc.: total assets
• Cumberland Pharmaceuticals Inc.: total liabilities
• Cumberland Pharmaceuticals Inc.: stockholders equity
• Cumberland Pharmaceuticals Inc.: cash and cash equivalents
• Cumberland Pharmaceuticals Inc.: net income or loss
• Cumberland Pharmaceuticals Inc.: operating cash flow
• Cumberland Pharmaceuticals Inc.: capital expenditure payments
• Cumberland Pharmaceuticals Inc.: revenue
• Cumberland Pharmaceuticals Inc.: contract revenue excluding tax
• Cumberland Pharmaceuticals Inc.: financing cash flow
• Cumberland Pharmaceuticals Inc.: investing cash flow
• Cumberland Pharmaceuticals Inc.: retained earnings or deficit
• Cumberland Pharmaceuticals Inc.: basic weighted-average shares
• Cumberland Pharmaceuticals Inc.: diluted weighted-average shares
• Cumberland Pharmaceuticals Inc.: diluted earnings per share
• Cumberland Pharmaceuticals Inc.: income tax expense or benefit
• Cumberland Pharmaceuticals Inc.: net property, plant and equipment
• Cumberland Pharmaceuticals Inc.: share-based compensation expense
• Cumberland Pharmaceuticals Inc.: operating income or loss
• Cumberland Pharmaceuticals Inc.: current assets
• Cumberland Pharmaceuticals Inc.: interest expense
• Cumberland Pharmaceuticals Inc.: current liabilities
• Cumberland Pharmaceuticals Inc.: current accounts payable
• Cumberland Pharmaceuticals Inc.: goodwill carrying amount
• Cumberland Pharmaceuticals Inc.: net finite-lived intangible assets
• Cumberland Pharmaceuticals Inc.: net current accounts receivable
• Cumberland Pharmaceuticals Inc.: common-stock repurchase payments
• Cumberland Pharmaceuticals Inc.: net inventory
• Cumberland Pharmaceuticals Inc.: research and development expense

Inspect the source

Entity

Cumberland Pharmaceuticals Inc. / CIK 0001087294

Captured

2026-09-20T05:21:29.619Z

SEC response SHA-256

b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))